{"id":{"repo_id":"bu","oai_identifier":"oai:open.bu.edu:2144/53101"},"canonical_url":"https://search.ndltd.org/etd/bu/oai:open.bu.edu:2144/53101","repository":{"repo_id":"bu","name":"Boston University","base_url":"https://open.bu.edu/oai/request"},"display":{"title":"Context dependent strategies for drug sensitization in the tumor microenvironment","abstract":"Tumor cells respond to their environment and the metabolites within it. These extrinsic factors, as well as the oncogenic mutations cancer cells harbor, determine the metabolic route cancer cells take to fuel biosynthesis and drive cellular replication. While our understanding of the metabolic liabilities of cancer cells in the tumor microenvironment (TME) has rapidly expanded, the contexts in which these metabolic limitations exist are still unclear. This dissertation aims to identify contexts in which tumor cells are limited in essential metabolites and to examine strategies to impede cancer cell survival by targeting these limitations. First, we sought to explore the environmental variables that determine tumor recurrence and reestablishment following tumor resection surgery (TRS). Our findings indicate TRS significantly alters aspartate metabolism and that the recovery of aspartate metabolic flux is necessary for uncontrolled cancer cell growth. Second, we explored strategies for overcoming cancer cell resistance to therapeutics that induce ferroptosis using a bioengineered iron-responsive mRNA (IRmRNA) system. The system allows for the selective expression of genes of interest in high labile iron contexts, including during the labile iron release that precedes ferroptosis. We find that this strategy may, in the future, allow for tissue-specific expression of therapeutic mRNAs in diseased tissue and prevent off-tissue expression in healthy organs. Finally, we explore the ability of endogenous miRNAs to improve the cell type specificity of a library of novel chemotherapeutics using functional genomics screens. We find that numerous miRNAs sensitize cancer cells in both a cell-specific and drug-specific manner. In summary, this work addresses the long-standing challenges in the medical treatment of tumors by establishing contexts in which tumor cells are sensitive to metabolic inhibition and identifying strategies to overcome drug resistance and off-tissue toxicity.","abstract_html":"Tumor cells respond to their environment and the metabolites within it. These extrinsic factors, as well as the oncogenic mutations cancer cells harbor, determine the metabolic route cancer cells take to fuel biosynthesis and drive cellular replication. While our understanding of the metabolic liabilities of cancer cells in the tumor microenvironment (TME) has rapidly expanded, the contexts in which these metabolic limitations exist are still unclear. This dissertation aims to identify contexts in which tumor cells are limited in essential metabolites and to examine strategies to impede cancer cell survival by targeting these limitations. First, we sought to explore the environmental variables that determine tumor recurrence and reestablishment following tumor resection surgery (TRS). Our findings indicate TRS significantly alters aspartate metabolism and that the recovery of aspartate metabolic flux is necessary for uncontrolled cancer cell growth. Second, we explored strategies for overcoming cancer cell resistance to therapeutics that induce ferroptosis using a bioengineered iron-responsive mRNA (IRmRNA) system. The system allows for the selective expression of genes of interest in high labile iron contexts, including during the labile iron release that precedes ferroptosis. We find that this strategy may, in the future, allow for tissue-specific expression of therapeutic mRNAs in diseased tissue and prevent off-tissue expression in healthy organs. Finally, we explore the ability of endogenous miRNAs to improve the cell type specificity of a library of novel chemotherapeutics using functional genomics screens. We find that numerous miRNAs sensitize cancer cells in both a cell-specific and drug-specific manner. In summary, this work addresses the long-standing challenges in the medical treatment of tumors by establishing contexts in which tumor cells are sensitive to metabolic inhibition and identifying strategies to overcome drug resistance and off-tissue toxicity.","abstract_has_math":false,"creators":["Mattes, Zachary Francis"],"institution":"Boston University","degree_name":"Doctor of Philosophy","degree_level":"doctoral","degree_discipline":"Chemistry","degree_department":null,"school":null,"contributors":[],"advisors":["Grinstaff, Mark W.","Varelas, Xaralabos"],"committee_chairs":[],"committee_members":[],"year":2024,"date_issued":"2024","date_published":"2024","updated_at":"2026-11-19T02:42:12Z","subjects":["Biochemistry","Cellular biology","Biomedical engineering","Cancer biology","Cancer metabolism","Tumor microenvironment"],"languages":["en_US"],"rights":["Attribution 4.0 International"],"rights_urls":["http://creativecommons.org/licenses/by/4.0/"],"identifier_entries":[],"person_identifier_entries":[{"key":"dc:identifier.orcid","label":"ORCID","values":["0000-0001-6344-6964"],"render_values":[{"text":"0000-0001-6344-6964","href":"https://orcid.org/0000-0001-6344-6964","code":true}]}]},"links":{"outbound_url":"https://hdl.handle.net/2144/53101","outbound_label":"Handle","outbound_source":"dc:identifier.uri","record_url":"https://hdl.handle.net/2144/53101","record_label":"Repository record","record_kind":"handle","record_source":"dc:identifier.uri","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://open.bu.edu/oai/request?verb=GetRecord&metadataPrefix=dim&identifier=oai%3Aopen.bu.edu%3A2144%2F53101","prefix":"dim"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Grinstaff, Mark W.","Varelas, Xaralabos"]},{"key":"dc:creator","label":"Author","values":["Mattes, Zachary Francis"]},{"key":"dc:identifier.orcid","label":"ORCID","values":["0000-0001-6344-6964"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2026-06-11T13:58:14Z"]},{"key":"dc:date.embargo","label":"Dc Date Embargo","values":["2028-06-10T00:00:00Z"]},{"key":"dc:date.issued","label":"Date","values":["2024"]},{"key":"dc:date.updated","label":"Dc Date Updated","values":["2026-06-10T22:10:39Z"]},{"key":"dc:type","label":"Dc Type","values":["Thesis/Dissertation"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Chemistry"]},{"key":"thesis:degree_level","label":"Degree Level","values":["doctoral"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Doctor of Philosophy"]},{"key":"thesis:institution_name","label":"Thesis Institution Name","values":["Boston University"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Biochemistry","Cellular biology","Biomedical engineering","Cancer biology","Cancer metabolism","Tumor microenvironment"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["en_US"]},{"key":"dc:rights","label":"Dc Rights","values":["Attribution 4.0 International"]},{"key":"dc:rights.uri","label":"Rights URI","values":["http://creativecommons.org/licenses/by/4.0/"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://hdl.handle.net/2144/53101"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["2024"]},{"key":"dc:description.abstract","label":"Abstract","values":["Tumor cells respond to their environment and the metabolites within it. These extrinsic factors, as well as the oncogenic mutations cancer cells harbor, determine the metabolic route cancer cells take to fuel biosynthesis and drive cellular replication. While our understanding of the metabolic liabilities of cancer cells in the tumor microenvironment (TME) has rapidly expanded, the contexts in which these metabolic limitations exist are still unclear. This dissertation aims to identify contexts in which tumor cells are limited in essential metabolites and to examine strategies to impede cancer cell survival by targeting these limitations. First, we sought to explore the environmental variables that determine tumor recurrence and reestablishment following tumor resection surgery (TRS). Our findings indicate TRS significantly alters aspartate metabolism and that the recovery of aspartate metabolic flux is necessary for uncontrolled cancer cell growth. Second, we explored strategies for overcoming cancer cell resistance to therapeutics that induce ferroptosis using a bioengineered iron-responsive mRNA (IRmRNA) system. The system allows for the selective expression of genes of interest in high labile iron contexts, including during the labile iron release that precedes ferroptosis. We find that this strategy may, in the future, allow for tissue-specific expression of therapeutic mRNAs in diseased tissue and prevent off-tissue expression in healthy organs. Finally, we explore the ability of endogenous miRNAs to improve the cell type specificity of a library of novel chemotherapeutics using functional genomics screens. We find that numerous miRNAs sensitize cancer cells in both a cell-specific and drug-specific manner. In summary, this work addresses the long-standing challenges in the medical treatment of tumors by establishing contexts in which tumor cells are sensitive to metabolic inhibition and identifying strategies to overcome drug resistance and off-tissue toxicity."]},{"key":"dc:title","label":"Title","values":["Context dependent strategies for drug sensitization in the tumor microenvironment"]}]}],"canonical_facts":{"dc:contributor.advisor":["Grinstaff, Mark W.","Varelas, Xaralabos"],"dc:creator":["Mattes, Zachary Francis"],"dc:date.accessioned":["2026-06-11T13:58:14Z"],"dc:date.embargo":["2028-06-10T00:00:00Z"],"dc:date.issued":["2024"],"dc:date.updated":["2026-06-10T22:10:39Z"],"dc:description":["2024"],"dc:description.abstract":["Tumor cells respond to their environment and the metabolites within it. These extrinsic factors, as well as the oncogenic mutations cancer cells harbor, determine the metabolic route cancer cells take to fuel biosynthesis and drive cellular replication. While our understanding of the metabolic liabilities of cancer cells in the tumor microenvironment (TME) has rapidly expanded, the contexts in which these metabolic limitations exist are still unclear. This dissertation aims to identify contexts in which tumor cells are limited in essential metabolites and to examine strategies to impede cancer cell survival by targeting these limitations. First, we sought to explore the environmental variables that determine tumor recurrence and reestablishment following tumor resection surgery (TRS). Our findings indicate TRS significantly alters aspartate metabolism and that the recovery of aspartate metabolic flux is necessary for uncontrolled cancer cell growth. Second, we explored strategies for overcoming cancer cell resistance to therapeutics that induce ferroptosis using a bioengineered iron-responsive mRNA (IRmRNA) system. The system allows for the selective expression of genes of interest in high labile iron contexts, including during the labile iron release that precedes ferroptosis. We find that this strategy may, in the future, allow for tissue-specific expression of therapeutic mRNAs in diseased tissue and prevent off-tissue expression in healthy organs. Finally, we explore the ability of endogenous miRNAs to improve the cell type specificity of a library of novel chemotherapeutics using functional genomics screens. We find that numerous miRNAs sensitize cancer cells in both a cell-specific and drug-specific manner. In summary, this work addresses the long-standing challenges in the medical treatment of tumors by establishing contexts in which tumor cells are sensitive to metabolic inhibition and identifying strategies to overcome drug resistance and off-tissue toxicity."],"dc:identifier.orcid":["0000-0001-6344-6964"],"dc:identifier.uri":["https://hdl.handle.net/2144/53101"],"dc:language.iso":["en_US"],"dc:rights":["Attribution 4.0 International"],"dc:rights.uri":["http://creativecommons.org/licenses/by/4.0/"],"dc:subject":["Biochemistry","Cellular biology","Biomedical engineering","Cancer biology","Cancer metabolism","Tumor microenvironment"],"dc:title":["Context dependent strategies for drug sensitization in the tumor microenvironment"],"dc:type":["Thesis/Dissertation"],"thesis:degree_discipline":["Chemistry"],"thesis:degree_level":["doctoral"],"thesis:degree_name":["Doctor of Philosophy"],"thesis:institution_name":["Boston University"]},"updated_at":"2026-11-19T02:42:12Z"}